LpMab-23-recognizing cancer-type podoplanin is a novel predictor for a poor prognosis of early stage tongue cancer

PURPOSE: We report that the reactivity of a novel monoclonal antibody LpMab-23 for human cancer-type podoplanin (PDPN) is a predictor for a poor prognosis of tongue cancer. PATIENTS AND METHODS: The association between LpMab-23-recognizing cancer-type PDPN expression and clinical/pathological featur...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyazaki, Akihiro, Nakai, Hiromi, Sonoda, Tomoko, Hirohashi, Yoshihiko, Kaneko, Mika K., Kato, Yukinari, Sawa, Yoshihiko, Hiratsuka, Hiroyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940393/
https://www.ncbi.nlm.nih.gov/pubmed/29765527
http://dx.doi.org/10.18632/oncotarget.24986

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940393/
https://www.ncbi.nlm.nih.gov/pubmed/29765527
http://dx.doi.org/10.18632/oncotarget.24986

Ejemplares similares